| Malignant neoplasm of prostate
Eligard vs Firmagon
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of prostate.Deep comparison between: Eligard vs Firmagon with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFirmagon has a higher rate of injection site reactions vs Eligard based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Firmagon but not Eligard, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eligard
Firmagon
At A Glance
SC injection
Every 1-6 months
GnRH agonist
SC injection
Every 28 days
GnRH receptor antagonist
Indications
- Malignant neoplasm of prostate
- Malignant neoplasm of prostate
Dosing
Malignant neoplasm of prostate 7.5 mg SC once every month; 22.5 mg SC once every 3 months; 30 mg SC once every 4 months; 45 mg SC once every 6 months. Injection site should vary periodically in the upper- or mid-abdominal area, upper buttocks, or another location with adequate subcutaneous tissue.
Malignant neoplasm of prostate Starting dose: 240 mg given as two SC injections of 120 mg each at 40 mg/mL; maintenance dose: 80 mg given as one SC injection at 20 mg/mL every 28 days beginning 28 days after the starting dose.
Contraindications
- Hypersensitivity to GnRH, GnRH agonist analogs, or any component of ELIGARD
- History of severe hypersensitivity to degarelix or any product component
Adverse Reactions
Most common (>2%) Hot flashes/sweats, malaise and fatigue, testicular atrophy, weakness, dizziness, nausea, urinary frequency, nocturia, pruritus, myalgia, gynecomastia, decreased libido
Injection site Transient burning/stinging, pain, erythema, bruising, pruritus, induration, ulceration
Postmarketing Pituitary apoplexy, convulsions, interstitial lung disease
Most common (>=10%) Injection site reactions (pain, erythema, swelling, induration), hot flashes, increases in serum transaminases and GGT
Postmarketing Decreased bone density
Pharmacology
Leuprolide acetate is a GnRH agonist that potently inhibits gonadotropin secretion with continuous dosing; chronic administration suppresses LH and FSH, reducing testosterone to below castrate threshold (<=50 ng/dL) in males within two to four weeks of treatment initiation.
GnRH receptor antagonist; degarelix binds reversibly to pituitary GnRH receptors, reducing the release of gonadotropins and consequently suppressing testosterone below the castration level of 50 ng/dL.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eligard
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (9/12)
Firmagon
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Eligard
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (2/8)
Firmagon
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Eligard
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Firmagon
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EligardView full Eligard profile
FirmagonView full Firmagon profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.